A recent study suggests that expedited drug approvals do not necessarily translate to faster reimbursement decisions, according to a Pink Sheet report.
According to the report, the study does not explicitly blame health technology assessment (HTA) processes and offers no clear reason for the discrepancy.
To read more on Pink Sheet, click here. (Paid subscription required)
